Extracellular Matrix Remodeling in Tumors: Forces beyond Fibroblasts
Cet article remet en question le modèle de progression tumorale centré sur les fibroblastes en examinant comment les cellules non-fibroblastiques peuvent modifier les caractéristiques biochimiques et biomécaniques des tumeurs et comment les stratégies thérapeutiques ciblant ces cellules pourraient renforcer l'immunité et enrayer l'évolution protumorale de la matrice extracellulaire
Aberrant extracellular matrix (ECM) remodeling in tumors is characterized by altered deposition, enzymatic cross-linking, degradation, and organization of matrix molecules that in turn can contribute directly to tumor invasiveness, immune evasion, and resistance to therapy. Traditionally, cancer-associated fibroblasts (CAF) have been considered the principal architects of ECM remodeling in tumors. However, the role of non-fibroblast cell populations in modulating ECM structure and function and how these processes intersect with immune regulation, metabolism, and metastasis are also crucial but currently underappreciated. Challenging the prevailing fibroblast-centric paradigm, this review provides an overview of how non-fibroblast cell types engage in dynamic cross-talk and collectively shape the biochemical and biomechanical landscape of tumors. Therapeutic strategies targeting these alternative stromal players could disrupt protumor ECM dynamics, enhance antitumor immunity, and restore tissue homeostasis. Thus, a comprehensive understanding of the intricate network of non-fibroblast stromal cells within the tumor microenvironment (TME) can help elucidate opportunities for precision medicine and personalized cancer care, leading to the development of innovative therapeutic interventions targeting the TME.
Cancer Research , résumé, 2026